Dr. Reddy’s debuts store brand Nicorette Lozenges
There's a new option hitting the market for retailers looking for a private brand nicotine lozenge for consumers quitting smoking. Dr. Reddy’s Labs has unveiled its private label equivalent of Nicorette Lozenges, nicotine polacrilex lozenges, in 2 mg and 4 mg dosage strengths.
The product will look to tap into the roughly $200 million in sales that IRI data says the branded product pulled in for the 52 weeks ended May 17. The product is offered in multiple pack sizes in both dosage strengths to meet consumers’ needs, Dr. Reddy’s said.
“The launch of nicotine polacrilex lozenges represents our continuing commitment to the OTC category of smoking cessation,” said Mark Kikuchi, Dr. Reddy’s CEO of North American Generics. “Nicotine polacrilex lozenges are an important addition to our current offering of nicotine replacement therapy including nicotine transdermal system patches, sold as Habitrol brand and various store brands. This launch truly demonstrates our ability to deliver on more complex dosage forms for the benefit of consumers who wish to quit smoking by reducing withdrawal symptoms, including nicotine cravings.”